Vyepti

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

Patient Height: _____*cm*

What is the ICD-10 code? _____

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

CVS Caremark Specialty Pharmacy ● 2211 Sanders Road NBT-6 ● Northbrook, IL 60062
Phone: 1-888-877-0518 ● Fax: 1-855-330-1720 ● www.caremark.com

Site of Service Questions:

A. Where will this drug be administered?
- ❑ Ambulatory surgical, *skip to Clinical Criteria Questions*
- ❑ Home infusion, *skip to Clinical Criteria Questions*
- ❑ Off-campus Outpatient Hospital, *Continue to B*
- ❑ On-campus Outpatient Hospital, *Continue to B*
- ❑ Physician office, *skip to Clinical Criteria Questions*
- ❑ Pharmacy, *skip to Clinical Criteria Questions*

B. Is the patient less than 14 years of age?
- ❑ Yes, *skip to Clinical Criteria Questions*
- ❑ No, *Continue to C*

C. Is this request to continue previously established treatment with the requested medication? ***ACTION REQUIRED: If No, please attach supporting clinical documentation.***
- ❑ Yes - This is a continuation of an existing treatment., *Continue to D*
- ❑ No - This is a new therapy request (patient has not received requested medication in the last 6 months)*., skip to Clinical Criteria Questions*

D. Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids, or other pre-medications) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion? ***ACTION REQUIRED: If Yes, please attach supporting clinical documentation.***
- ❑ Yes, *skip to Clinical Criteria Questions*
- ❑ No, *Continue to E*

E. Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment? ***ACTION REQUIRED: If Yes, please attach supporting clinical documentation.***
- ❑ Yes, *skip to Clinical Criteria Questions*
- ❑ No, *Continue to F*

F. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? ***ACTION REQUIRED: If Yes, please attach supporting clinical documentation.***
- ❑ Yes, *skip to Clinical Criteria Questions*
- ❑ No, *Continue to G*

G. Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? ***ACTION REQUIRED: If Yes, please attach supporting clinical documentation.***
- ❑ Yes, *skip to Clinical Criteria Questions*
- ❑ No, *Continue to H*

H. Are ***all*** alternative infusion sites (pharmacy, physician office, ambulatory care, etc.) **greater than** 30 miles from the patient's home? ***ACTION REQUIRED: If Yes, please attach supporting documentation.***
- ❑ Yes, *continue to Clinical Criteria Questions*
- ❑ No, *continue to Clinical Criteria Questions*

Clinical Criteria Questions:

1. Is the requested drug being prescribed for the preventive treatment of migraine in an adult patient?
❒ Yes, *Continue to 2*
❒ No, *Continue to 10*

2. Has the patient received at least 3 months of treatment with the requested drug?
❒ Yes, *Continue to 3*
❒ No, *Continue to 6*

3. Is this request for any of the following: A) Aimovig, B) Ajovy, C) Emgality 120 mg, D) Vyepti?
❒ Yes, *Continue to 4*
❒ No, *No Further Questions*

4. Has the patient had a reduction in migraine days per month from baseline?
❒ Yes, *Continue to 5*
❒ No, *Continue to 5*

5. Does the patient require MORE than the plan allowance of any of the following: A) 1 injection (70 mg or 140 mg) per month of Aimovig, B) 3 injections (225 mg each) per 3 months of Ajovy, C) 1 injection (120 mg) per month of Emgality, D) 3 single dose vials (100 mg each) for intravenous infusion per 3 months of Vyepti?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

6. Is this request for any of the following: A) Aimovig, B) Ajovy, C) Vyepti?
❒ Yes, *Continue to 7*
❒ No, *Continue to 8*

7. Does the patient require MORE than the plan allowance of any of the following: A) 1 injection (70 mg or 140 mg) per month of Aimovig, B) 3 injections (225 mg each) per 3 months of Ajovy, C) 3 single dose vials (100 mg each) for intravenous infusion per 3 months of Vyepti?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

8. Is this request for Emgality 120 mg?
❒ Yes, *Continue to 9*
❒ No, *No Further Questions*

9. Does the patient require MORE than the plan allowance of 4 injections (120 mg each) per first 3 months of Emgality (i.e., loading dose of 2 injections followed by 1 injection per month)?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

10. Is this request for Emgality 100 mg for the treatment of episodic cluster headache in an adult patient?
❒ Yes, *Continue to 11*
❒ No, *Continue to 11*

11. Has the patient received at least 3 weeks of treatment with the requested drug?
❒ Yes, *Continue to 12*
❒ No, *Continue to 14*

12. Has the patient had a reduction in weekly cluster headache attack frequency from baseline?
❒ Yes, *Continue to 13*
❒ No, *Continue to 13*

13. Does the patient require MORE than the plan allowance of 3 injections (100 mg each) per month of Emgality?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

14. Has the patient experienced an inadequate treatment response to ANY of the following: A) sumatriptan (nasal or subcutaneous), B) zolmitriptan (nasal or oral)?
❒ Yes, *Continue to 16*
❒ No, *Continue to 15*

15. Has the patient experienced an intolerance to or does the patient have a contraindication to ANY of the following: A) sumatriptan (nasal or subcutaneous), B) zolmitriptan (nasal or oral)?
❒ Yes, *Continue to 16*
❒ No, *Continue to 16*

16. Does the patient require MORE than the plan allowance of 3 injections (100 mg each) per month of Emgality?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**